|Bid||123.43 x 1200|
|Ask||123.65 x 800|
|Day's Range||122.39 - 124.95|
|52 Week Range||85.58 - 146.15|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.23|
PRINCETON, N.J. & CAMBRIDGE, Mass., Jun 11, 2021--BMS & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a Virtual R&D Day for analysts and investors on June 22, 2021. The virtual event will take place from 8:00 a.m. to approximately 11:00 a.m. EDT.
Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). The data were presented at the American Thoracic Society 2021 International Conference. Investigators reported that patients experienced consistent or improved responses in multiple efficacy endpoints when treated with sotatercept for up to 48 weeks. Additionally, patients re-randomized to receive sotatercept on top of background therapies during weeks 24 to 48, after receiving placebo plus stable background therapy during the first 24 weeks of the trial, experienced clinical improvements consistent with those seen in the initial placebo-controlled treatment period. Sotatercept was generally well-tolerated. In the trial, serious treatment-emergent adverse events were reported in 28% of patients, and 9% of patients had adverse events that led to study discontinuation. See the ATS 2021 presentation here. Price Action: XLRN shares are down 0.55% at $123.9 during the market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaTreace Medical's Lapiplasty 3D Associated With Early Weightbearing After Foot Surgery, Interim Data ShowsNew Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.